The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / RA Patients May Not Receive Needed Osteoporosis Screening & Treatment

RA Patients May Not Receive Needed Osteoporosis Screening & Treatment

May 4, 2018 • By Arthritis Care & Research

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients with rheumatoid arthritis (RA) are at increased risk for the development of osteoporosis, due to inflammation-associated osteoclast activation and other reasons. Glucocorticoid use is also a well-established cause of osteoporosis, with osteoporotic fractures contributing to health-related costs and functional loss, morbidity and mortality for RA patients. To raise awareness to these concerns, the ACR published recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis in 2010. The recommendations included calcium/vitamin D supplementation, use of a Fracture Risk Assessment Tool (FRAX) for all patients and bisphosphonate treatment for patients at a high risk for fracture.

You Might Also Like
  • A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis
  • Osteoporosis Screening Is Underutilized Despite Recommendations
  • Routine Osteoporosis Screening in Men Proves Cost-Effective

Previous research noted a treatment gap, with only 30% of estimated eligible patients (65% of postmenopausal women and 52% of men age 50 years or older) receiving bisphosphonates. This treatment gap may also exist for RA patients for whom the need for osteoporosis screening and treatment interventions remains higher than the general population. Additionally, it is unknown if the 2010 ACR recommendations improved osteoporosis care of RA patients compared with patients at lower risk.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a new study published in Arthritis Care & Research, May 2018, Gulsen Ozen, MD, of the University of Nebraska Medical Center, Omaha, and colleagues assessed the frequency, trends and predictors of osteoporosis treatment and screening in patients with RA compared with patients with osteoarthritis (OA). Researchers used data from the National Data Bank for Rheumatic Diseases for the longitudinal prospective observational study, with care defined as screening or receiving osteoporosis treatment (with the exception of calcium/vitamin D) or screening. The cohort consisted of 11,669 RA patients and 2,829 OA patients who received care and follow-up from 2003 through 2014.

The Results
“Approximately half of the RA patients were potential candidates for osteoporosis treatment by the 2010 ACR glucocorticoid-induced osteoporosis prevention [recommendations] or 2014 National Osteoporosis Foundation guideline. However, only approximately half of these patients ever received an osteoporosis medication,” write the authors.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Osteoporosis screening and treatment was reported in 67.4% of 11,669 RA patients and in 64.6% of 2,829 OA patients during a median of 5.5 (two to nine) years of follow-up. Of the patients for whom treatment was recommended, 48.4% of RA patients and 17.6% of OA patients reported osteoporosis medication use—approximately 55% overall. When compared with OA patients, RA patients were not more likely to undergo osteoporosis treatment or screening, after accounting for differences in socio-demographic features, BMI, glucocorticoid treatment, functional disability and FRAX 10-year major osteoporotic fracture risk categories.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Arthritis Care & Research, fracture risk, fracture risk factors, Fractures, Glucocorticoid-Induced Osteoporosis, Glucocorticoids, Osteoporosis, Rheumatoid Arthritis (RA)

You Might Also Like:
  • A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis
  • Osteoporosis Screening Is Underutilized Despite Recommendations
  • Routine Osteoporosis Screening in Men Proves Cost-Effective
  • BMI Feasible As Pre-Screening Tool for Osteoporosis in Women

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)